

Developing speech-based clinical measures that generalize

Visar Berisha, PhD

Associate Professor

College of Engineering and College of Health Solutions @ ASU

Chief Analytics Officer @ Aural Analytics



Disclosures

Co-founder and Chief Analytics Officer at Aural Analytics, Inc

ASU Research is funded by NIH, NSF, ONR, DoD, JTMF Foundation, and industry partners

Relevant industry partners include Boehringer Ingelheim and Google

Collaborators

Julie M. Liss, PhD



Current Students and Postdocs



Pouria Saidi

Postdoctoral Researcher



Vikram C.M.

Postdoctoral Researcher



Weizhi Li

Ph.D. Student



Jianwei Zhang

Ph.D. Student



Lingfeng Xu

Ph.D. Student



Rohit Voleti

Ph.D. Student



Pranav Ambadi

Ph.D. Student



Prad Kadambi

Ph.D. Student



Sean Kinahan

Ph.D. Student



Kelvin Tran


Ph.D. Student

Shira Hahn, PhD

Gabriela Stegmann, PhD

Chelsea Krantsevich


The promise of speech-based clinical measures



We don't know where the **information** is in this **high-dimensional, high-velocity data** stream

The current approach: data-driven supervised learning

The starting point is a labeled dataset




Extract features using existing tools

OpenSMILE
wav2vec
NLP features
Mel spectra






Predict a clinical variable of interest



If the estimated accuracy is “**good**”, then **publish**; otherwise, relegate it to the **proverbial file-drawer**

Purely data-driven solutions are not likely to generalize




Clinical data is sparsely available and these models provide **no natural way to make connections to the existing knowledge-base**

Berisha et al "Digital medicine and the curse of dimensionality." *Nature npj Digital Medicine*, October 2021.


Berisha et al, "Are reported accuracies in the clinical speech machine learning literature overoptimistic", *Interspeech 22*.

Classification between healthy controls and patient group X based on data from modality Y


X = Alzheimer's, Y = Neuroimaging




X = Schizophrenia, Y = Neuroimaging







X = ADHD, Y = Neuroimaging



X = ASD, Y = Neuroimaging



X = Alzheimer's, Y = Neuroimaging



[Subscribe](#) [Latest Issues](#)

SCIENTIFIC AMERICAN®

[Cart 0](#) [Sign In](#) | [Newsletters](#)

[Coronavirus](#) [Health](#) [Mind & Brain](#) [Environment](#) [Technology](#) [Space & Physics](#) [Video](#) [Podcasts](#) [Opinion](#) [Store](#) [Q](#)

ARTIFICIAL INTELLIGENCE | OPINION

AI in Medicine Is Overhyped


AI models for health care that predict disease are not as accurate as reports might suggest.
Here's why

By Visar Berisha, Julie Liss on October 19, 2022

Multiple modalities

Arbabshirani, M, et al. "Single subject prediction of brain disorders in neuroimaging: Promises and pitfalls." *Neuroimage* 145 (2017): 137-165.
Vabalas, Andrius, et al. "Machine learning algorithm validation with a limited sample size." *PloS one* 14.11 (2019): e0224365.

A measurement model for clinical speech analytics



Feature engineering

Machine learning and signal processing
used to **develop measures for theoretical
constructs of clinical interest**

Articulation

Prosody

Respiration

...

Memory

Simple
model

Simple
model

Simple
model

Simple
model

Motor-speech assessment

Vital Capacity
Prediction
(VCP)

Behavioral health
assessment

Cognitive
screener


Each model is
clinically validated

Goldsack, Jennifer C., et al. "Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs)." *Nature npj digital Medicine* 3.1 (2020): 1-15.

Case study: Assessing motor and respiratory symptoms in ALS

Collected remotely
on personal devices

Standard clinical
scale



In Pridopidine trial, analytics suggested **slowing of decline in several markers related to speech and bulbar function** in participants taking Pridopidine, while the **primary endpoint did not meet the criterion for success**

Stegmann, G.M., Hahn, S., Liss, J., Shefner, J., Rutkove, S., Shelton, K., Duncan, C.J. and Berisha, V., 2020. Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis. *Nature npj Digital Medicine*, 3(1), pp.1-5.

Stegmann, Gabriela M., et al. "Estimation of forced vital capacity using speech acoustics in patients with ALS." *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration* 22.sup1 (2021): 14-21.

Beyond ALS

Alzheimer's disease and related dementias

Stegmann, Gabriela, et al. "Automated semantic relevance as an indicator of cognitive decline: Out-of-sample validation on a large-scale longitudinal dataset." *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* 14.1 (2022): e12294.


Schizophrenia and Bipolar Disorder

Voleti, Rohit, et al. "Language analytics for assessment of mental health status and functional competency." *Schizophrenia Bulletin*. In press. Pre-print available: <https://psyarxiv.com/yw7c6/download?format=pdf>

Parkinson's disease and other motor disorders

Liss, Julie M., Sue LeGendre, and Andrew J. Lotto. "Discriminating dysarthria type from envelope modulation spectra." *Journal of Speech, Language, and Hearing Research*, (2010).

Speech and fine motor for measuring early PD



Thank you

